



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com


www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



SRI-37330

Cat. No.:	HY-142114
CAS No.:	2322245-42-9
Molecular Formula:	C ₁₆ H ₁₉ F ₃ N ₄ O ₂ S
Molecular Weight:	388.41
Target:	Others
Pathway:	Others
Storage:	4°C, stored under nitrogen
	* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (257.46 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		2.5746 mL	12.8730 mL	25.7460 mL
		5 mM		0.5149 mL	2.5746 mL	5.1492 mL
		10 mM		0.2575 mL	1.2873 mL	2.5746 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 5 mg/mL (12.87 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 5 mg/mL (12.87 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	SRI-37330 is an orally bioavailable thioredoxin-interacting protein (TXNIP) inhibitor. SRI-37330 inhibits glucagon secretion and function, reduces hepatic glucose production and reverses hepatic steatosis. SRI-37330 can be used for type 2 diabetes research ^[1] .
IC ₅₀ & Target	TXNIP ^[1]
In Vitro	SRI-37330 (1 μM, 24 h) inhibits the activity of the human TXNIP promoter in INS-1 cells^[1]. SRI-37330 (1 μM, 24 h) inhibits Mrna and protein levels of TXNIP in INS-1 cells^[1]. SRI-37330 (5 μM, 24 h) inhibits polymerase II (Pol II) binding to the E-box motif region of the TXNIP promoter^[1]. SRI-37330 (5 μM, 24 h) lowers glucagon secretion in TC1-6 cells^[1]. SRI-37330 (0-5 μM, 24 h) inhibits glucagon-induced glucose output from primary hepatocytes^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

RT-PCR^[1]

Cell Line:	INS-1 cells
Concentration:	1 μ M
Incubation Time:	24 h
Result:	Inhibited endogenous TXNIP mRNA expression with an IC ₅₀ of 0.64 μ M.

In Vivo

SRI-37330 (100 mg/kg, p.o., in drinking water, 3 weeks) decreases glucagon secretion and action and blocks hepatic glucose output^[1].

SRI-37330 (100 mg/kg, p.o., in drinking water, 3 weeks) is well tolerated in male C57BL/6J mice^[1].

SRI-37330 (100 mg/kg, p.o., in drinking water, 3 weeks) reverses obesity- and STZ-induced diabetes and hepatic steatosis in mice^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6J mice ^[1]
Dosage:	100 mg/kg
Administration:	Oral administration (p.o.), in drinking water, 3 weeks.
Result:	Lowered serum glucagon levels, inhibited hepatic glucose production and improved glucose homeostasis in mice.

CUSTOMER VALIDATION

- SSRN. 2024 Nov 15.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Thielen LA, et al. Identification of an Anti-diabetic, Orally Available Small Molecule that Regulates TXNIP Expression and Glucagon Action. Cell Metab. 2020 Sep 1;32(3):353-365.e8.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA